The nomenclature of monoclonal antibodies (mAbs) is based on a structured system established by the World Health Organization (WHO) and adopted by regulatory agencies. It provides standardized naming to describe the source, target, and class of the antibody. The name of a monoclonal antibody typically ends in -mab and is divided into several components:
1. Prefix
The prefix is unique and has no specific meaning. It is created to differentiate the antibody from others and ensure the name is unique.
2. Target or Disease Class Infix
This infix indicates the target or the system the antibody acts on. Examples include:
-ci-: Cardiovascular system (e.g., abciximab)
-li-: Immune system (e.g., nivolumab)
-tu-: Tumor (e.g., trastuzumab)
-vi-: Viral targets (e.g., palivizumab)
3. Source or Species Infix
This infix indicates the origin of the antibody or how it was engineered:
-o-: Mouse (e.g., muromonab)
-xi-: Chimeric (mouse/human, e.g., rituximab)
-zu-: Humanized (e.g., trastuzumab)
-u-: Fully human (e.g., adalimumab)
4. Suffix
All monoclonal antibodies end with -mab to indicate that it is a monoclonal antibody.
Example Breakdown
⭕️⭕️⭕️⭕️⭕️
معنا مثلاً في سؤال 11 من الملف
الدواء Rituximab
Rituximab
Prefix: "Ritu" (random, unique)
Target: -tu- (tumor)
Source: -xi- (chimeric)
Suffix: -mab (monoclonal antibody)

⭕️⭕️⭕️⭕️⭕️⭕️
كذلك معنا سؤال 27 من الملف
العلاج Adalimumab
Adalimumab
Prefix: "Ada" (random, unique)
Target: -li- (immune system)
Source: -u- (human)
Suffix: -mab
⭕️⭕️⭕️⭕️⭕️
ايضاً معنا مثلاً في سؤال 22 من الملف
الدواء Bamlanivimab
Target: -vi- (Virus "COVID-19")
Suffix: -mab (monoclonal antibody)

🔹 إن شاء الله وصلت لكم المعلومة بالشكل المطلوب 🩵.
➖➖➖➖➖➖➖➖➖➖
#Drug_Discovery
#Ph_اللجنة_العلمية_صيدلـ33ـة